Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis

Aims of the study were to find vascular markers of inflammation and endothelial damage during the course of severe sepsis in septic patients and the effects of treatment with anti-inflammatory medication (such as Drotregocin alfa (activated)). Another aim is to find new markers and gene polymorphisms for prognosis and mortality of patients with severe sepsis. The hypothesis is that higher plasma concentrations of certain markers in septic patients are associated with a higher mortality rate.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sepsis Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

1. Medical Department

University Hospital Mannheim, Mannheim, 68167, Germany

About this study

During the past years many investigators have focused on the immunological changes in sepsis disease, and great attention has been paid to the development of practicable means of immunomonitoring. Human activated protein C (Drotrecogin alfa (activated)), an important coagulation inhibitor plays a major role in regulating microvascular coagulation, inflammation and immunology. Little is known about prognostic vascular biomarkers during the time course of patients with severe sepsis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

SIRS-Criteria
Proven Infection
One sepsis-induced organ-failure
Adults <18 years old

Exclusion criteria

Anemia
Pregnancy
Blood donor in the last 3 month

Treatment and study plan

vein puncture

Procedure

comparison of different inflammatory markers in the blood of septic patients

Primary outcomes

New Prognostic markers for septic patients

Time frame: until 300 Patients are included

Sponsors and collaborators

Lead sponsor

Universitätsmedizin Mannheim

Other

Registry information

Important dates

Study start: 2003
Primary completion: 2011
Study completion: 2011
First posted: Sep 22, 2005
Registry last updated: Feb 16, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed